The Bewildering Antitubercular Action of Pyrazinamide.

Animals Antitubercular Agents / pharmacology Clinical Trials as Topic Drug Development Drug Resistance, Multiple, Bacterial Humans Mice Mutation Mycobacterium tuberculosis / drug effects Pyrazinamide / pharmacology Tuberculosis, Multidrug-Resistant / drug therapy
antimicrobial activity coenzyme A drug resistance drug resistance mechanisms drug susceptibility mode of action pyrazinamide tuberculosis

Journal

Microbiology and molecular biology reviews : MMBR
ISSN: 1098-5557
Titre abrégé: Microbiol Mol Biol Rev
Pays: United States
ID NLM: 9706653

Informations de publication

Date de publication:
20 05 2020
Historique:
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 13 7 2021
Statut: epublish

Résumé

Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease relapse rates, PZA is considered an irreplaceable component of standard first-line short-course therapy for drug-susceptible TB and second-line treatment regimens for multidrug-resistant TB. Despite over 60 years of research on PZA and its crucial role in current and future TB treatment regimens, the mode of action of this unique drug remains unclear. Defining the mode of action for PZA will open new avenues for rational design of novel therapeutic approaches for the treatment of TB. In this review, we discuss the four prevailing models for PZA action, recent developments in modulation of PZA susceptibility and resistance, and outlooks for future research and drug development.

Identifiants

DOI: 10.1128/MMBR.00070-19 PMID: 32132245 PMC: PMC7062198
pubmed: 32132245
pii: 84/2/e00070-19
doi: 10.1128/MMBR.00070-19
pmc: PMC7062198
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Pyrazinamide 2KNI5N06TI

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI123146
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007741
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Drugs. 1982 Aug;24(2):118-32
pubmed: 6749471
PLoS One. 2019 Feb 28;14(2):e0212798
pubmed: 30817803
ACS Infect Dis. 2017 Nov 10;3(11):807-819
pubmed: 28991455
World J Microbiol Biotechnol. 2014 Nov;30(11):2821-8
pubmed: 25034468
Antimicrob Agents Chemother. 2013 Mar;57(3):1428-33
pubmed: 23295931
Am Rev Tuberc. 1952 May;65(5):511-8
pubmed: 14924173
J Exp Med. 1956 Nov 1;104(5):763-802
pubmed: 13367342
J Biol Chem. 2008 Jul 11;283(28):19329-41
pubmed: 18490451
Emerg Infect Dis. 2017 Mar;23(3):491-495
pubmed: 28221108
Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32
pubmed: 21282447
Int J Tuberc Lung Dis. 2006 Mar;10(3):317-22
pubmed: 16562713
Dis Model Mech. 2015 Jun;8(6):603-10
pubmed: 26035868
Antimicrob Agents Chemother. 2016 May 23;60(6):3276-82
pubmed: 26953190
Infect Genet Evol. 2019 Aug;72:147-150
pubmed: 30447296
Am Rev Respir Dis. 1975 Jun;111(6):845-8 CONTD
pubmed: 49163
Lancet. 2012 Sep 15;380(9846):986-93
pubmed: 22828481
MMWR Morb Mortal Wkly Rep. 2001 Apr 20;50(15):289-91
pubmed: 11330495
J Clin Microbiol. 2013 Jan;51(1):383
pubmed: 23269982
Antimicrob Agents Chemother. 2014 Dec;58(12):7258-63
pubmed: 25246400
Science. 2003 Oct 24;302(5645):654-9
pubmed: 14576437
Antimicrob Agents Chemother. 1997 Mar;41(3):540-3
pubmed: 9055989
ACS Infect Dis. 2017 Sep 8;3(9):634-644
pubmed: 28762275
Clin Infect Dis. 2016 Nov 1;63(suppl 3):S63-S74
pubmed: 27742636
Antimicrob Agents Chemother. 2015 Sep;59(9):5267-77
pubmed: 26077261
Tubercle. 1987 Jun;68(2 Suppl):41-6
pubmed: 3318048
Antimicrob Agents Chemother. 2010 Dec;54(12):5323-8
pubmed: 20876380
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28760903
J Antimicrob Chemother. 2018 Jul 1;73(7):1750-1754
pubmed: 29528413
Emerg Microbes Infect. 2014 Aug;3(8):e58
pubmed: 26038753
Protein Expr Purif. 2002 Aug;25(3):533-40
pubmed: 12182836
Am Rev Tuberc. 1954 Oct;70(4):748-54
pubmed: 13197751
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855077
Antimicrob Agents Chemother. 1995 Jun;39(6):1269-71
pubmed: 7574514
Mol Microbiol. 2010 Apr;76(2):365-77
pubmed: 20199601
Antimicrob Agents Chemother. 1981 Oct;20(4):556-7
pubmed: 6805419
Int J Tuberc Lung Dis. 2015 Feb;19(2):179-84
pubmed: 25574916
J Mol Biol. 2007 May 4;368(3):845-52
pubmed: 17376482
Am Rev Respir Dis. 1992 May;145(5):1223-5
pubmed: 1586071
Am Rev Tuberc. 1952 May;65(5):523-46
pubmed: 14924175
Br J Dis Chest. 1981 Oct;75(4):331-57
pubmed: 7030377
Science. 2003 Apr 4;300(5616):127-30
pubmed: 12677067
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630203
Antimicrob Agents Chemother. 2007 Jul;51(7):2430-5
pubmed: 17485499
Lancet Infect Dis. 2015 Nov;15(11):1357-60
pubmed: 26321650
Nature. 2012 May 06;485(7399):526-9
pubmed: 22622583
Proc Soc Exp Biol Med. 1952 Apr;79(4):563-5
pubmed: 14920496
Antimicrob Agents Chemother. 2007 Feb;51(2):752-4
pubmed: 17101678
Nat Rev Microbiol. 2007 Jan;5(1):39-47
pubmed: 17160001
J Commun Dis. 2006 Mar;38(3):288-98
pubmed: 17373362
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4956-60
pubmed: 27270287
J Clin Microbiol. 2012 Nov;50(11):3726-8
pubmed: 22895038
Am Rev Respir Dis. 1962 Oct;86:503-12
pubmed: 13942996
Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53
pubmed: 25622149
Int J Antimicrob Agents. 2017 Feb;49(2):183-188
pubmed: 28012685
Microbiol Mol Biol Rev. 2004 Sep;68(3):501-17, table of contents
pubmed: 15353567
Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43
pubmed: 26574016
Structure. 2013 Jul 2;21(7):1251-7
pubmed: 23746808
Science. 1996 Feb 16;271(5251):990-3
pubmed: 8584937
EMBO J. 2000 Dec 1;19(23):6612-21
pubmed: 11101533
J Med Microbiol. 2002 Jan;51(1):42-49
pubmed: 11800471
FEBS J. 2008 Dec;275(24):6149-58
pubmed: 19016865
Emerg Microbes Infect. 2017 Apr 26;6(4):e27
pubmed: 28442749
J Med Assoc State Ala. 1956 Oct;26(4):81-6
pubmed: 13367704
Nat Med. 2016 May;22(5):531-8
pubmed: 27043495
Tuberculosis (Edinb). 2015 Sep;95(5):608-12
pubmed: 26071666
Nat Med. 2008 Aug;14(8):849-54
pubmed: 18641659
Int J Tuberc Lung Dis. 2003 Jan;7(1):6-21
pubmed: 12701830
East Afr Med J. 1973 Dec;50(12):672-80
pubmed: 4132127
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263056
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14458-63
pubmed: 22908248
PLoS One. 2013 Jul 30;8(7):e68942
pubmed: 23935911
Antimicrob Agents Chemother. 2012 Jan;56(1):446-57
pubmed: 21986820
J Clin Microbiol. 2014 Jan;52(1):291-7
pubmed: 24131688
Mol Microbiol. 2014 Aug;93(4):617-28
pubmed: 24976069
J Bacteriol. 1981 Dec;148(3):926-32
pubmed: 6796563
Am Rev Tuberc. 1952 May;65(5):519-22
pubmed: 14924174
Arch Biochem Biophys. 1992 Jun;295(2):318-26
pubmed: 1586161
Nat Med. 1996 Jun;2(6):662-7
pubmed: 8640557
Nat Commun. 2017 Sep 19;8(1):588
pubmed: 28928454
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28584158
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29686155
BMC Infect Dis. 2017 Jul 12;17(1):491
pubmed: 28697808
ACS Infect Dis. 2016 Sep 9;2(9):616-626
pubmed: 27759369
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5
pubmed: 22927424
Dis Model Mech. 2015 Jun;8(6):591-602
pubmed: 26035867
ACS Infect Dis. 2015 May 8;1(5):203-214
pubmed: 26086040
BMC Infect Dis. 2017 Nov 6;17(1):711
pubmed: 29110640
Expert Opin Investig Drugs. 2013 Jul;22(7):927-32
pubmed: 23687915
Sci Rep. 2017 Jul 21;7(1):6135
pubmed: 28733601
Antimicrob Agents Chemother. 2011 Nov;55(11):5354-7
pubmed: 21876062
Nat Med. 2000 Sep;6(9):1043-7
pubmed: 10973326
PLoS Pathog. 2014 Mar 06;10(3):e1003994
pubmed: 24603869
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28438933
Trends Microbiol. 2016 Nov;24(11):862-871
pubmed: 27430191
J Med Microbiol. 2004 Aug;53(Pt 8):769-773
pubmed: 15272064
Am Rev Tuberc. 1956 Oct;74(4):552-65
pubmed: 13362862
ACS Infect Dis. 2016 Apr 8;2(4):251-267
pubmed: 27227164
J Bacteriol. 2002 Apr;184(8):2167-72
pubmed: 11914348
Nucleic Acids Symp Ser (Oxf). 2007;(51):369-70
pubmed: 18029740
J Biol Chem. 2016 Apr 1;291(14):7465-76
pubmed: 26858247
Antimicrob Agents Chemother. 2004 Jul;48(7):2736-8
pubmed: 15215139
Lancet. 1974 Aug 3;2(7875):237-40
pubmed: 4135686
Emerg Microbes Infect. 2017 Feb 15;6(2):e8
pubmed: 28196969
PLoS One. 2015 Jul 28;10(7):e0133869
pubmed: 26218737
Antimicrob Agents Chemother. 2015 Mar;59(3):1690-5
pubmed: 25583712
Antimicrob Agents Chemother. 2015 Jul;59(7):4012-9
pubmed: 25896710
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27872068
Am Rev Respir Dis. 1989 Nov;140(5):1189-93
pubmed: 2817579
Sci Rep. 2017 Jun 19;7(1):3790
pubmed: 28630430
J Antimicrob Chemother. 2015 Apr;70(4):1115-23
pubmed: 25505005
Microbiol Spectr. 2014 Aug;2(4):MGM2-0023-2013
pubmed: 26104205
Bioorg Med Chem Lett. 2011 Aug 15;21(16):4804-7
pubmed: 21775138
Ann Am Thorac Soc. 2015 May;12(5):674-9
pubmed: 25664920
Antimicrob Agents Chemother. 2015 Dec;59(12):7320-6
pubmed: 26369957
Antimicrob Agents Chemother. 2003 Nov;47(11):3672-3
pubmed: 14576145
mBio. 2014 Oct 21;5(5):e01819-14
pubmed: 25336456
J Infect Dis. 2011 Dec 15;204(12):1951-9
pubmed: 22021624
J Bacteriol. 1999 Apr;181(7):2044-9
pubmed: 10094680
J Lab Clin Med. 1948 Oct;33(10):1249-53
pubmed: 18886322
Biochim Biophys Acta. 2012 Sep;1818(9):2108-19
pubmed: 22564680
Adv Med Sci. 2016 Mar;61(1):63-71
pubmed: 26521205
Microbiol Spectr. 2014 Aug;2(4):MGM2-0003-2013
pubmed: 26104214
Antimicrob Agents Chemother. 1996 Jan;40(1):14-6
pubmed: 8787871
Clin Infect Dis. 2003 Feb 15;36(4):453-60
pubmed: 12567303
Nat Prod Rep. 2004 Dec;21(6):695-721
pubmed: 15565250
Antimicrob Agents Chemother. 1983 Oct;24(4):600-1
pubmed: 6418066
Antimicrob Agents Chemother. 2012 Jun;56(6):3181-95
pubmed: 22470120
Emerg Microbes Infect. 2013 Jun;2(6):e34
pubmed: 26038471
ACS Infect Dis. 2017 Jul 14;3(7):492-501
pubmed: 28271875
Infect Genet Evol. 2013 Oct;19:1-6
pubmed: 23770140
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6
pubmed: 18388355
Antimicrob Agents Chemother. 2012 Oct;56(10):5186-93
pubmed: 22825123
Expert Rev Anti Infect Ther. 2015 May;13(5):593-603
pubmed: 25746054
Science. 2012 Mar 16;335(6074):1366-9
pubmed: 22422985
J Cell Biochem. 2018 Mar;119(3):2567-2578
pubmed: 28980723
Am Rev Tuberc. 1953 Mar;67(3):391-5
pubmed: 13031058
Am Rev Tuberc. 1955 Jan;71(1):140-3
pubmed: 14350174
Gut Pathog. 2009 Feb 09;1(1):4
pubmed: 19338684
Chemotherapy. 2007;53(5):338-43
pubmed: 17785970
J Bacteriol. 2014 Jun;196(12):2123-30
pubmed: 24706739
Prog Lipid Res. 2005 Mar-May;44(2-3):125-53
pubmed: 15893380
Nucleic Acids Res. 2003 Dec 1;31(23):6996-7002
pubmed: 14627832
Nat Med. 2015 Oct;21(10):1223-7
pubmed: 26343800
Microbiology. 2001 Apr;147(Pt 4):1017-1024
pubmed: 11283297
RNA. 2006 Feb;12(2):248-55
pubmed: 16373482
Science. 2011 Sep 16;333(6049):1630-2
pubmed: 21835980
J Exp Med. 2018 Aug 6;215(8):1975-1986
pubmed: 30018074
J Antimicrob Chemother. 2003 Nov;52(5):790-5
pubmed: 14563891
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94
pubmed: 25216832
Tuberculol Thorac Dis. 1953 Dec;14(1):149-54
pubmed: 13146825
EMBO J. 2012 Mar 21;31(6):1529-41
pubmed: 22286948
Biochemistry. 1989 May 30;28(11):4523-30
pubmed: 2669958
Appl Microbiol Biotechnol. 2010 Feb;85(6):1629-42
pubmed: 19956944
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13454-9
pubmed: 15340139
Diagn Microbiol Infect Dis. 2016 Mar;84(3):207-11
pubmed: 26775806
Chem Biodivers. 2012 Nov;9(11):2582-96
pubmed: 23161636
Emerg Microbes Infect. 2017 Oct 11;6(10):e86
pubmed: 29018250
J Clin Microbiol. 2013 Jan;51(1):382
pubmed: 23269981
Antimicrob Agents Chemother. 1997 Mar;41(3):636-40
pubmed: 9056006
J Membr Biol. 1984;82(2):179-90
pubmed: 6096547
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10282-7
pubmed: 23733947

Auteurs

Elise A Lamont (EA)

Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

Nicholas A Dillon (NA)

Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

Anthony D Baughn (AD)

Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA abaughn@umn.edu.
ORCID: 0000-0003-1188-4238

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrazines › Pyrazinamide › The Bewildering Antitubercular Action of Pyrazinamide.
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › The Bewildering Antitubercular Action of Pyrazinamide.